Lauren C. Harshman MD, Assistant Professor of Medicine, Harvard Medical School, Dana-Farber, presents a strong case for a neoadjuvant/adjvuant approach to priming the immune system before surgery at the 2016 annual International Kidney Cancer Symposium.
Phase 3 Perioperative Nivolumab in M0 RCC (PROSPER RCC, ECOG –ACRIN 8143)
